“…In symptomatic visceral leishmaniasis, there is an increased antibody response, both in dogs and in humans, and recombinant antigen-based assays can thus be used ( Dhom-Lemos et al., 2019 ; Lévêque et al., 2020 ; Pereira et al., 2020 ). The challenge is asymptomatic leishmaniasis, in which we face a low serology against the protozoan, the tests showing a reduced sensitivity, as well as a cross-reactivity with other pathologies such as tuberculosis, Chagas disease, or malaria, which reduces the tests’ specificity ( Daltro et al., 2019 ; Rodrigues et al., 2019 ). Recently, the rLiHyQ protein was identified in the antigens of Leishmania spp.…”